Elliott B. Grossbard

R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation

Sylvia Braselmann, Vanessa Taylor, H. Zhao et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 511 citations

Life Sciences, Immunology, Pharmacology +17

An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis

Michael E. Weinblatt, Arthur Kavanaugh, Mark C. Genovese et al. · New England Journal of Medicine · 2010 · 377 citations

Medicine, Pharmacology, Pharmacotherapy +15

Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve‐week, randomized, placebo‐controlled trial

Michael E. Weinblatt, Arthur Kavanaugh, Rubén Burgos‐Vargas et al. · Arthritis & Rheumatism · 2008 · 336 citations

Medicine, Immunology, Pharmacology +12

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three‐month randomized, placebo‐controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents

Mark C. Genovese, Arthur Kavanaugh, Michael E. Weinblatt et al. · Arthritis & Rheumatism · 2010 · 209 citations

Medicine, Pharmacology, Pharmacotherapy +17

Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor

Polly Pine, Betty Chang, Nathan Schoettler et al. · Clinical Immunology · 2007 · 207 citations

Medicine, Immunology, Pharmacotherapy +16